PMID- 28500559
OWN - NLM
STAT- MEDLINE
DCOM- 20180419
LR  - 20210103
IS  - 1573-7373 (Electronic)
IS  - 0167-594X (Linking)
VI  - 133
IP  - 3
DP  - 2017 Jul
TI  - Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a 
      retrospective case series.
PG  - 561-569
LID - 10.1007/s11060-017-2466-0 [doi]
AB  - A single institution retrospective evaluation of nivolumab following disease 
      progression on bevacizumab in adults with recurrent glioblastoma (GBM) with an 
      objective of determining progression free survival (PFS). There is no accepted 
      therapy for recurrent GBM after failure of bevacizumab. 16 adults, ages 
      52-72 years (median 62), with recurrent GBM were treated. All patients had 
      previously been treated with surgery, concurrent radiotherapy and temozolomide, 
      and post-radiotherapy temozolomide. Bevacizumab (with or without lomustine) was 
      administered to all patients at first recurrence. Patients were treated with 
      nivolumab only (3 mg/kg) once every 2 weeks at second recurrence. One cycle of 
      nivolumab was defined as 2 treatments. Neurological evaluation was performed 
      bi-weekly and neuroradiographic assessment every 4 weeks. A total of 37 treatment 
      cycles (median 2) were administered of nivolumab in which there were 14 Grade 2 
      adverse events (AEs) and Grade 3 AEs in two patients. No Grade 4 or 5 AEs were 
      seen. Following 1 month of nivolumab, seven patients demonstrated progressive 
      disease and discontinued therapy. No patient demonstrated a response though nine 
      patients demonstrated neuroradiographic stable response. Survival in the entire 
      cohort ranged from 2 to 6 months with a median of 3.5 months (CI 2.8, 4.2). 
      Median and 6-month PFS at 6 months was 2.0 months (range 1-5 months; CI 1.3, 2.7) 
      and 0% respectively. Nivolumab salvage therapy demonstrated no survival advantage 
      in patients with recurrent bevacizumab refractory GBM emphasizing a continued 
      unmet need in neuro-oncology.
FAU - Chamberlain, Marc C
AU  - Chamberlain MC
AUID- ORCID: 0000-0002-1613-1123
AD  - Division of Neuro-Oncology, Department of Neurology and Neurosurgery, Fred 
      Hutchinson Cancer Center, Seattle Cancer Care Alliance, University of Washington, 
      825 Eastlake Ave E, MS: G4-940, Seattle, WA, 98109, USA. 
      marccchamberlain@gmail.com.
FAU - Kim, Bryan T
AU  - Kim BT
AD  - Department of Neurology, University of Washington, Seattle, WA, USA.
LA  - eng
PT  - Journal Article
DEP - 20170512
PL  - United States
TA  - J Neurooncol
JT  - Journal of neuro-oncology
JID - 8309335
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Bevacizumab/*therapeutic use
MH  - Brain Neoplasms/diagnostic imaging/*therapy
MH  - Disease Progression
MH  - Female
MH  - Glioblastoma/diagnostic imaging/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy
MH  - Nivolumab
MH  - Retrospective Studies
MH  - Salvage Therapy/adverse effects
MH  - Survival Analysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Bevacizumab refractory
OT  - Immune checkpoint inhibitor
OT  - Nivolumab
OT  - Recurrent glioblastoma
EDAT- 2017/05/14 06:00
MHDA- 2018/04/20 06:00
CRDT- 2017/05/14 06:00
PHST- 2016/09/30 00:00 [received]
PHST- 2017/05/06 00:00 [accepted]
PHST- 2017/05/14 06:00 [pubmed]
PHST- 2018/04/20 06:00 [medline]
PHST- 2017/05/14 06:00 [entrez]
AID - 10.1007/s11060-017-2466-0 [pii]
AID - 10.1007/s11060-017-2466-0 [doi]
PST - ppublish
SO  - J Neurooncol. 2017 Jul;133(3):561-569. doi: 10.1007/s11060-017-2466-0. Epub 2017 
      May 12.